The 2020 race towards SARS-CoV-2 specific vaccines

Area of Science:

• Vaccinology
• Virology
• Biotechnology

Background:

• The COVID-19 pandemic necessitates rapid development of vaccines and therapeutics.
• Advances in biotechnology and genetic engineering are crucial for understanding SARS-CoV-2 and developing countermeasures.
• Identifying viral antigens and characterizing capsid structure are key for effective vaccine design.

Purpose of the Study:

• To review the progress of 52 distinct vaccines against SARS-CoV-2.
• To analyze registered clinical trials based on international safety and efficacy criteria.
• To discuss the benefits, risks, and challenges associated with various vaccine types and their distribution.

Main Methods:

• Analysis of registered clinical trials for SARS-CoV-2 vaccines (as of November 04, 2020).
• Review of diverse vaccine platforms including whole-virus, subunit, mRNA, DNA, live vector, and plant-based VLP vaccines.
• Evaluation of safety, efficacy, potency, and potential side effects.

Main Results:

• An update on the ongoing global race to develop 52 SARS-CoV-2 vaccines is presented.
• Focus on clinical trials meeting international safety and efficacy standards.
• Discussion encompasses various vaccine types, their requirements, benefits, and risks.

Conclusions:

• The review highlights the progress and challenges in developing diverse SARS-CoV-2 vaccines.
• Emphasis on the importance of data integrity, cross-validation, and rigorous safety/efficacy studies.
• Long-term effectiveness, distribution, and safety remain critical considerations for global COVID-19 vaccine deployment.